IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1689
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$175.3B
Marc N. Casper
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines. Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids. Laboratory Products and Services segment provides laboratory refrigerators and freezers.
Headcount
130.0K
HQ Base
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = TMO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TMO THERMO FISHER SCIENTIFIC INC. | 52 | 51 | 60 | 47 | 30.1x | 31.0x | 12.5% | 6.2% | 41.0% | 17.1% | 14.9% | 5.5% | 0.4% | 70.0x | $175.3B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
THERMO FISHER SCIENTIFIC INC. (TMO) receives a "Hold" rating with a composite score of 52.0/100. It ranks #1689 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Waltham, Massachusetts
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for TMO.
View All RatingsROIC 5.0% vs WACC 8.4% (spread -3.3%)
GM 41% vs sector 44%, OM 17% vs sector 3%
Capital turnover 0.33x, R&D intensity 3.2%
Rev growth 6%, 10yr history
Interest coverage 5.6x, Net debt/EBITDA 17.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate THERMO FISHER SCIENTIFIC INC. (TMO) as a Hold with a composite score of 52.0/100 at a current price of $515.75. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
THERMO FISHER SCIENTIFIC INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.0/100 places it at rank #1689 in our full universe.
Narrow
Medium
Standard
Fair Value
Gross margins of 41% signal strong pricing power.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
THERMO FISHER SCIENTIFIC INC. represents a hold based on multi-factor quantitative performance.
Our model assigns THERMO FISHER SCIENTIFIC INC. a Hold rating, with a composite score of 52.0/100 and 3 out of 5 stars. Ranked #1689 of 7,333 stocks, TMO presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 51/100, TMO shows adequate but unremarkable business quality. The company reports a return on equity of 12.5% (sector avg: -1.9%), gross margins of 41.0% (sector avg: 44.1%), net margins of 14.9% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
TMO's value score of 60/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 30.09x, an EV/EBITDA of 31.03x, a P/B ratio of 3.76x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
THERMO FISHER SCIENTIFIC INC.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 5.5% vs. a sector average of 6.7% and a return on assets of 6.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TMO is currently showing below-average momentum at 47/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 5.5% year-over-year, while a beta of 0.91 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
TMO shows good financial stability with a score of 82/100. Key stability metrics include a beta of 0.91 and a debt-to-equity ratio of 70.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 49/100 for TMO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 70.00x). With a $175.3B market cap (large-cap), THERMO FISHER SCIENTIFIC INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
TMO offers a modest dividend yield of 0.4%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
THERMO FISHER SCIENTIFIC INC. is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1689 of 7,333 overall (77th percentile). Key comparisons include ROE of 12.5% exceeding the -1.9% sector median and operating margins of 17.1% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TMO currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (82) vs Investment (36) — closing this gap could shift the rating.
EV/EBITDA 171% ABOVE SECTOR MEDIAN
ROE 758% BELOW SECTOR MEDIAN
Gross Margin 7% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g
The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories
The global Assisted Reproductive Technology (ART) market is poised for significant growth, with a value of USD 29.59 billion in 2025, projected to reach USD 49.30 billion by 2033 at a 6.59% CAGR. Key drivers include rising infertility rates, technological advances, and increased awareness of fertility treatments. ART encompasses IVF, ICSI, cryopreservation, and more to aid in conception. Major players like Thermo Fisher, CooperSurgical, and Merck KGaA are propelling innovations and market reach.
Thermo Fisher Scientific (TMO) is in focus after announcing a data collaboration with Datavant that connects real world data to clinical research, an effort aimed at supporting stronger evidence generation for pharma and biotech clients. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s recent data partnerships and the planned Clario acquisition come as the stock shows mixed momentum, with a 7 day share price return of 2.30% but a 30 day share price return...
Thermo Fisher Scientific reported Q4 2025 adjusted EPS of $6.57, beating expectations of $6.45, with quarterly sales of $12.22 billion up 7% YoY. The company projects 2026 revenue growth of 4-6% and adjusted EPS of $24.22-$24.80, up 6-8%. The pending $8.875 billion Clario acquisition could add 20-25 cents to 2026 EPS. However, shares fell 3.2% following the announcement.